Surrey-Based Glass Pharms Secures Multimillion-Pound Medical Cannabis Deal with Releaf

Glass Pharms, a leading medical cannabis producer from Surrey, has signed a groundbreaking multimillion-pound deal with Releaf, an online clinic. This partnership aims to bolster the UK’s medical cannabis sector, securing a reliable supply of high-quality cannabis products for patients in need.

A New Standard in UK Medical Cannabis

Glass Pharms will provide Releaf with 145kg of medical-grade cannabis as part of this deal, marking the largest agreement of its kind in the UK. Tim Kirby, CEO of Releaf, described the partnership as a major milestone for both his company and the entire UK medical cannabis industry. He emphasized that this collaboration addresses the key issue of prescription reliability, which has been a challenge for the sector.

• 145kg of high-quality medical-grade cannabis will be supplied.
• Releaf’s patient base is expected to grow beyond the current 45,000 people in the UK.
• The agreement highlights the increasing acceptance of cannabis as a valid healthcare solution.

Scaling Up to Meet Growing Demand

Releaf’s clinic is already seeing over 100 patients daily, with demand expected to soar in the coming year. The partnership with Glass Pharms is essential to supporting this growth and ensuring that patients have consistent access to cannabis-based treatments. Glass Pharms’ domestic production capability will play a crucial role in solving supply chain issues that have long plagued the UK market.

Tim Kirby noted that the partnership is about more than just supply; it’s about setting new standards in the industry. With reliable access to domestically grown cannabis, Releaf hopes to provide better care for its patients while helping the sector mature.

A Boost for Patient Care in the UK

The UK’s medical cannabis industry has often struggled with prescription availability and consistency. By partnering with Glass Pharms, Releaf aims to address these challenges head-on. The domestic supply chain ensures that patients won’t face delays or shortages, which can have serious consequences for those relying on cannabis for their treatment.

With an estimated 45,000 people already receiving medical cannabis in the UK, this deal could significantly increase the sector’s capacity. As more patients turn to cannabis for treatment, partnerships like this will be critical for supporting the industry’s growth.